This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
Journal: Progress in Neuro-Psychopharmacology & Biological Psychiatry 35(4):1041-1044 (2011)
Authors: O Rosenberg, M Isserles, Y Levkovitz, M Kotler, A Zangen, P.N Dannon
Deep transcranial magnetic stimulation (dTMS) is an emerging and promising treatment for major depression. In our study, we explored the effectiveness of a second antidepressant course of dTMS in major depression.
To evaluate whether a second course of dTMS would be effective.
Eight depressive patients who relapsed after a previous successful deep TMS course expressed their wish to be treated again. Upon their request, they were recruited and treated with 20 daily sessions of dTMS at 20 Hz using the BrainsWay’s H1 coil. The Hamilton depression rating scale (HDRS), Hamilton anxiety rating scale (HARS) and the Beck depression inventory (BDI) were used weekly to evaluate the response to treatment.
Similar to the results obtained in the first course of treatment, the second course of treatment (after relapse) induced significant reductions in HDRS, HARS and BDI scores, compared to the ratings measured prior to treatment. The magnitude of response in the second course was smaller relative to that obtained in the first course of treatment.
These results suggest that depressive patients who previously responded well to deep TMS treatment are likely to respond again. However, the slight reduction in the magnitude of the response in the second treatment raises the question of whether tolerance or resistance to this treatment may eventually develop.